Evaluation of comorbid autoimmune diseases among patients and family members enrolled in the Alopecia
Areata Registry, Biobank & Clinical Trials Network.
Vitiligo and alopecia areata are both common, T cell-driven autoimmune diseases of the skin. Recognizing
similarities and differences between these diseases will promote a more complete understanding of their
pathogenesis as well as the development of new treatments.
Summary, outcomes and action plan presented by Dr. Angela Christiano at the end of the two-day Alopecia Areata Research Summit held November 14-15, 2016 in New York, NY.
To date, the Registry has epidemiology and quality-of-life data from 11,180 self-registered patients with 4,196
well-characterized samples of DNA, lymphoblast lines, and sera for future research studies.
2015 06-02 Steering group 'Personalized Medicine: eligible or not'Alain van Gool
Update for the steering group of the project "Personalized Medcine: eligble or not?", aiming to define whether and how to implement pharmacogenetic screening by first line care practitioners.
2015 09-14 Precision Medicine 2015, London, Alain van GoolAlain van Gool
Outline of my view hoe personalized health(care) is more than just targeted medicines, also including personal motivation and actions towards disease prevention. It also outlines 4 key factors that should be in order for optimal personalized health(care): 1. start with patients first, 2. Accelerate translation research to application, 3. Copy best practice, 4. Spread the word.
Vitiligo and alopecia areata are both common, T cell-driven autoimmune diseases of the skin. Recognizing
similarities and differences between these diseases will promote a more complete understanding of their
pathogenesis as well as the development of new treatments.
Summary, outcomes and action plan presented by Dr. Angela Christiano at the end of the two-day Alopecia Areata Research Summit held November 14-15, 2016 in New York, NY.
To date, the Registry has epidemiology and quality-of-life data from 11,180 self-registered patients with 4,196
well-characterized samples of DNA, lymphoblast lines, and sera for future research studies.
2015 06-02 Steering group 'Personalized Medicine: eligible or not'Alain van Gool
Update for the steering group of the project "Personalized Medcine: eligble or not?", aiming to define whether and how to implement pharmacogenetic screening by first line care practitioners.
2015 09-14 Precision Medicine 2015, London, Alain van GoolAlain van Gool
Outline of my view hoe personalized health(care) is more than just targeted medicines, also including personal motivation and actions towards disease prevention. It also outlines 4 key factors that should be in order for optimal personalized health(care): 1. start with patients first, 2. Accelerate translation research to application, 3. Copy best practice, 4. Spread the word.
A slide series to learn and appreciate the importance and the potential of Personalized/Individualized Genomic Medicine. It briefly goes through the idea of biotechnology and the advancements we have made in biology and technology. A series of applications for genomic medicine is then explored, not failing to mention the challenges we have to overcome as well, for the next medical revolution.
A case for personalized medicine is presented.
From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...Dexter Hadley
Lecture Objectives:
1) To use examples from my research to define and introduce the ideals of precision medicine and digital health. 2) To introduce how large scale population-wide analysis of data can be used to facilitate these two ideals. 3) To introduce how freely available open data can be used to facilitate these two ideals. 4) To show how mobile technology can be used to facilitate these two ideals.
With recent advances in Healthcare, Personalized medicine has become a buzzword. The customization of health care, based on DNA sequencing, patient's environmental information, can lead to more efficient treatments.
By integrating various sources of data, personalized medicine improves all aspects of healthcare from prevention to monitoring.
Dr. Angela Christiano presents an update on genetic and immunological studies in alopecia areata. Dr. Christiano’s research has helped clarify the immunologic mechanisms behind the disease. Now, early clinical trials with existing drugs that specifically target these mechanisms are showing promising hair regrowth. Dr. Christiano is the Richard and Mildred Rhodebeck Professor of Dermatology and Professor of Genetics & Development, and Vice Chair for Basic Science Research in Dermatology at Columbia University.
Precision Medicine: Opportunities and Challenges for Clinical TrialsMedpace
The momentum and muscle behind "finding the right drug for the right patient at the right dose" has further escalated with President Barack Obama’s announcement of a $215 million dollar Precision Medicine Initiative earlier this year. In this webinar, Dr. Frank Smith will explore advances in precision medicine and how it is affecting clinical research. As a pediatric hematologist/oncologist, he will use his extensive clinical and research background as a backdrop for the discussion.
Topics will include:
The evolution of "personalized medicine" to "precision medicine"
How state-of-the-art molecular biology is creating new diagnostic and prognostic strategies
How these new strategies are helping inform the design of clinical trials
Case study: How precision medicine is improving clinical trials in hematology and oncology
Personalized Medicine: Are we there yet?Reid Robison
Slides on the future of healthcare, entitled "Personalized Medicine: Are we there yet?" form a lecture given by Reid Robison, MD MBA at Brigham Young University in the College of Life Sciences in December 2014. The presentation covers the arrival of genome-guided precision medicine as well as the digital health movement and the shift towards a patient-centric, consumer-driven healthcare system.
The usability of STAMP in drug development Arete-Zoe, LLC
Arete-Zoe in cooperation with Stuttgart University
Study authors: Veronika Valdova, Ronald L Sheckler, Asim Abdulkhaleq and Stefan Wagner (Jonathan M Fishbein)
Presentation of synopsis: Veronika Valdova
Presented at STAMP team meeting, PSCI, ACRES on February 26, 2016
Date held: February 12, 2015
Presented by: Deb Davison, Genomic Health
Topics discussed:
The latest in genomic testing and its role in cancer treatment
The most recent results from Genomic Health’s second independent clinical validation study of Oncotype DX® in DCIS patients
Q&A session about the implications of this research
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
Cancer care is increasingly tailored to individual patients, who can undergo genetic or biomarker testing soon after diagnosis, to determine which treatments have the best chance of shrinking or eliminating tumours.
In this webinar, a pathologist and clinical oncologist discuss:
● how they are using these new tests,
● how they communicate results and treatment options to patients and caregivers, and
● how patients can be better informed on the kinds of tests that are in development or in use across Canada
View the video: https://youtu.be/_Wai_uMQKEQ
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Correlation between Demographic, Socio-economic, and Cancer-Specific Factors with Quality of Life Scores among Newly-Diagnosed Cancer Patients of the Medical Oncology Clinics of the Philippine General Hospital Cancer Institute
https://www.actamedicaphilippina.org/issue/1102
Personalized Medicine – From Theory to Practice as presented by keynote speaker Ralph Snyderman, MD; Director of the Center for Research on Prospective Health Care, James B. Duke Professor of Medicine, Chancellor Emeritus, Duke University
A slide series to learn and appreciate the importance and the potential of Personalized/Individualized Genomic Medicine. It briefly goes through the idea of biotechnology and the advancements we have made in biology and technology. A series of applications for genomic medicine is then explored, not failing to mention the challenges we have to overcome as well, for the next medical revolution.
A case for personalized medicine is presented.
From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...Dexter Hadley
Lecture Objectives:
1) To use examples from my research to define and introduce the ideals of precision medicine and digital health. 2) To introduce how large scale population-wide analysis of data can be used to facilitate these two ideals. 3) To introduce how freely available open data can be used to facilitate these two ideals. 4) To show how mobile technology can be used to facilitate these two ideals.
With recent advances in Healthcare, Personalized medicine has become a buzzword. The customization of health care, based on DNA sequencing, patient's environmental information, can lead to more efficient treatments.
By integrating various sources of data, personalized medicine improves all aspects of healthcare from prevention to monitoring.
Dr. Angela Christiano presents an update on genetic and immunological studies in alopecia areata. Dr. Christiano’s research has helped clarify the immunologic mechanisms behind the disease. Now, early clinical trials with existing drugs that specifically target these mechanisms are showing promising hair regrowth. Dr. Christiano is the Richard and Mildred Rhodebeck Professor of Dermatology and Professor of Genetics & Development, and Vice Chair for Basic Science Research in Dermatology at Columbia University.
Precision Medicine: Opportunities and Challenges for Clinical TrialsMedpace
The momentum and muscle behind "finding the right drug for the right patient at the right dose" has further escalated with President Barack Obama’s announcement of a $215 million dollar Precision Medicine Initiative earlier this year. In this webinar, Dr. Frank Smith will explore advances in precision medicine and how it is affecting clinical research. As a pediatric hematologist/oncologist, he will use his extensive clinical and research background as a backdrop for the discussion.
Topics will include:
The evolution of "personalized medicine" to "precision medicine"
How state-of-the-art molecular biology is creating new diagnostic and prognostic strategies
How these new strategies are helping inform the design of clinical trials
Case study: How precision medicine is improving clinical trials in hematology and oncology
Personalized Medicine: Are we there yet?Reid Robison
Slides on the future of healthcare, entitled "Personalized Medicine: Are we there yet?" form a lecture given by Reid Robison, MD MBA at Brigham Young University in the College of Life Sciences in December 2014. The presentation covers the arrival of genome-guided precision medicine as well as the digital health movement and the shift towards a patient-centric, consumer-driven healthcare system.
The usability of STAMP in drug development Arete-Zoe, LLC
Arete-Zoe in cooperation with Stuttgart University
Study authors: Veronika Valdova, Ronald L Sheckler, Asim Abdulkhaleq and Stefan Wagner (Jonathan M Fishbein)
Presentation of synopsis: Veronika Valdova
Presented at STAMP team meeting, PSCI, ACRES on February 26, 2016
Date held: February 12, 2015
Presented by: Deb Davison, Genomic Health
Topics discussed:
The latest in genomic testing and its role in cancer treatment
The most recent results from Genomic Health’s second independent clinical validation study of Oncotype DX® in DCIS patients
Q&A session about the implications of this research
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
Cancer care is increasingly tailored to individual patients, who can undergo genetic or biomarker testing soon after diagnosis, to determine which treatments have the best chance of shrinking or eliminating tumours.
In this webinar, a pathologist and clinical oncologist discuss:
● how they are using these new tests,
● how they communicate results and treatment options to patients and caregivers, and
● how patients can be better informed on the kinds of tests that are in development or in use across Canada
View the video: https://youtu.be/_Wai_uMQKEQ
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Correlation between Demographic, Socio-economic, and Cancer-Specific Factors with Quality of Life Scores among Newly-Diagnosed Cancer Patients of the Medical Oncology Clinics of the Philippine General Hospital Cancer Institute
https://www.actamedicaphilippina.org/issue/1102
Personalized Medicine – From Theory to Practice as presented by keynote speaker Ralph Snyderman, MD; Director of the Center for Research on Prospective Health Care, James B. Duke Professor of Medicine, Chancellor Emeritus, Duke University
Elsevier Medical Graph – mit Machine Learning zu Precision MedicineRising Media Ltd.
Elsevier Health Analytics entwickelt den Medical Knowledge Graph, welcher Korrelationen zwischen Krankheiten und zwischen Krankheiten und Behandlungen darstellt. Auf einem Gesamtdatensatz von sechs Millionen anonymisierten Patienten, beobachtbar über sechs Jahre, haben wir über 2000 Modelle erstellt, welche die Entwicklung von Krankheiten prognostizieren. Jedes Modell ist adjustiert für mehr als 3000 Kovariablen. Dazu kam ein Boosting Algorithmus mit Variablenselektion zum Einsatz. Die Betas der selektierten Variablen wurden extrahiert, getestet hinsichtlich Kausalität und Signifikanz, und daraus wurde die erste Version des Medical Graphen mit über 2000 Krankheitsknoten und 25.000 Effekt-Kanten gebaut. Der Graph wird aktuell in der Praxis getestet, mit dem Ziel, dem Arzt eine patienten-individuelle Entscheidungsunterstützung für die Behandlung zu geben.
Day 2 Big Data panel at the NIH BD2K All Hands 2016 meetingWarren Kibbe
Big data in oncology and implications for open data, open science, rapid innovation, data reuse, reproducibility and data sharing. Cancer Moonshot, Precisions Medicine Initiative (PMI), the Genomic Data Commons, NCI Cloud Pilots, NCI-DOE Pilots, and the Cancer Research Data Ecosystem.
NCI Cancer Imaging Program - Cancer Research Data EcosystemWarren Kibbe
Given to the NCI Cancer Imaging Program monthly telecon on January 9th, 2017. NCI Genomic Data Commons, Beau Biden Cancer Moonshot Blue Ribbon Panel, Cancer Research Data Ecosystem and the role of imaging in precision medicine
Nci clinical genomics data sharing ncra sept 2016Warren Kibbe
Gave an update on the Cancer Research Data Ecosystem, the Genomic Data Commons, Cloud Pilots, incentives for data sharing in cancer research to the NCI Council of Research Advocates (NCRA) on Monday, September 26th, 2016
Medical Imaging: 8 Opportunities for technology entrepreneurs and investorsHealthstartup
There is tremendous opportunity currently to conduct advanced analysis of imaging data for diagnostic and treatment planning purposes, to combine imaging data from various sources and to share images for better medical collaboration. While medical imaging used to be the exclusive domain of large multinational medical devices companies, startups are entering the fray with software-based solutions and clever use of open-source or consumer-based technologies.
National Cancer Data Ecosystem and Data SharingWarren Kibbe
Grand Rounds at the Siteman Cancer Center at Washington University. Highlighting the Genomic Data Commons and the National Cancer Data Ecosystem defined by the Cancer Moonshot Blue Ribbon Panel
Introducing VSWarehouse - A Scalable Genetic Data Warehouse for VarSeqGolden Helix Inc
As Precision Medicine is taking off, the number of samples in a testing lab and the associated data volume is increasing exponentially. In order to organize the data and build a knowledge base of cases that can be used for future analysis as well as ongoing research, labs need to leverage state of the art warehousing technology.
Cancer Moonshot, Data sharing and the Genomic Data CommonsWarren Kibbe
Gave the inaugural Informatics Grand Rounds at City of Hope on September 8th. NIH Commons, Genomic Data Commons, NCI Cloud Pilots, Cancer Moonshot and rationale for changing incentives around data sharing all discussed.
2017 03-07 World Economic Forum - Dutch topsector Life Science Health, The Ha...Alain van Gool
Update to the World Economic Forum of the Dutch approach towards personalized medicine and health, leveraging the strong infrastructure components we have in the Netherlands and addressing the needs of society to maintain or restore personal health..
This investigation implicated raw flour as a source of an outbreak of STEC infections. Although it is low-moisture food, raw flour can be a vehicle of foodborne pathogens
Information Genetic Content (IGC): a comprehensive discovery platform for dis...Thermo Fisher Scientific
We developed Information Genetic Content (IGC), a comprehensive
knowledgebase and discovery tool for human genes and genetic disorders
research use. IGC comprises three components: the Disease-Association
Database (DAD), the Gene Scoring Algorithm (GSA), and the Virtual Panel
Library (VPL). The DAD module contains over 400,000 associations
between over 17,000 genes and 15,000 Mendelian and complex diseases
from both expert-curated and text-mined data. The DAD module also
features a hierarchical organization of human diseases using a UMLScontrolled
vocabulary, permitting queries at any level of the disease
ontology hierarchy. The GSA module aims to prioritize genes for a specific
disease of interest. This gene scoring algorithm is distinctive in the way it
combines the strength of association and the number of associated
diseases to provide an unbiased score for each gene. In conjunction with
the DAD module, the GSA module is able to produce a list of ranked genes
for one or more diseases at any level of the disease hierarchy. The VPL
module generates optimal gene grouping by disease classification using
hierarchical-clustering-based network analysis. Genes that are involved in
the same pathological pathways are grouped into the same cluster.
"How Scientific Wellness will Drive The Future of Health" - Nathan Price (Pro...Hyper Wellbeing
"How Scientific Wellness will Drive The Future of Health" - Nathan Price (Professor, Institute of Systems Biology)
Delivered at the inaugural Hyper Wellbeing Summit, 14th November 2016, Mountain View, California.
For more information including details of subsequent events, please visit http://hyperwellbeing.com
The summit was created to foster a community around an emerging industry - Wellness as a Service (WaaS). Consumer technologies, in particular wearables and mobile, are powering a consumer revolution. A revolution to turn health and wellness into platform delivered services. A revolution enabling consumer data-driven disease risk reduction. A revolution extending health care past sick care towards consumer-led lifelong health, wellness and lifestyle optimization.
WaaS newsletter sign-up http://eepurl.com/b71fdr
@hyperwellbeing
The Impact of Lymph Node Dissection on Survival in Intermediate- and High-Ris...semualkaira
Aimed to evaluate the therapeutic effect of pelvic lymph node dissection (PLND) on survival and determine the predictors of lymph node involvement (LNI) in patients with intermediate- or high-risk prostate cancer (PCa) treated with Radical Prostatectomy
The Impact of Lymph Node Dissection on Survival in Intermediate- and High-Ris...semualkaira
Aimed to evaluate the therapeutic effect of pelvic lymph node dissection (PLND) on survival and determine the
predictors of lymph node involvement (LNI) in patients with intermediate- or high-risk prostate cancer (PCa) treated with Radical
Prostatectomy
Capstone thesis submitted for undergraduate studies on the utility of genomic surveying tools in improving sudden cardiac arrest risk stratification and prediction of sudden cardiac death.
Searching for phenotypes of sepsis an application of machine learning to elec...TÀI LIỆU NGÀNH MAY
Để xem full tài liệu Xin vui long liên hệ page để được hỗ trợ
: https://www.facebook.com/thuvienluanvan01
HOẶC
https://www.facebook.com/garmentspace/
https://www.facebook.com/thuvienluanvan01
https://www.facebook.com/thuvienluanvan01
tai lieu tong hop, thu vien luan van, luan van tong hop, do an chuyen nganh
Similar to Comorbidities Present in the Alopecia Areata Registry, Biobank & Clinical Trials Network (20)
Dr. Angela Christiano presented an update on genetic and immunological studies in alopecia areata. Her research is focused on defining the genetic basis of alopecia areata to clarify how the disease develops—a key initial step toward creating novel therapies. Dr. Christiano is the Richard and Mildred Rhodebeck Professor of Dermatology, Genetics and Development, Vice Chair for Basic Science Research in Dermatology, and Director of the Center for Human Genetics at Columbia University.
Dr. Leslie Castelo-Soccio presented an overview of what parents need to know about alopecia areata in children and adolescents, including the differences between pediatric and adult patients, and the risks and benefits of current and evolving off-label treatment options. Dr. Castelo-Soccio is Assistant Professor of Pediatrics and Dermatology at the University of Pennsylvania School of Medicine and head of the Pediatric Hair Clinic and Director of Research in Pediatric Dermatology at the Children’s Hospital of Philadelphia. Her clinical and academic research focus is on pediatric hair disorders.
Dr. Maria Hordinsky presented an overview of key things adults need to know about alopecia areata, including the risks and benefits of current and evolving off-label treatment options. Dr. Hordinsky is Professor and Head of the Department of Dermatology at the University of Minnesota. She is recognized for her clinical expertise in alopecia areata and hair diseases.
Dr. Natasha Mesinkovska, NAAF’s Chief Scientific Officer, presented the latest progress of NAAF’s Treatment Development Program and how your involvement is critical to developing treatments for alopecia areata. In addition to overseeing NAAF’s research efforts, Dr. Mesinkovska is Director of Clinical Research in Dermatology at the University of California Irvine.
Presented at the joint International Eczema Council and National Alopecia Areata Foundation Symposium, "Atopic Dermatitis and Alopecia Areata: Comparison and Contrast”, held during the 2019 Annual American Academy of Dermatology meeting in Washington, DC to explore the similarities and differences between these two common but complex skin diseases and the implications from bench to bedside.
Presented at the joint International Eczema Council and National Alopecia Areata Foundation Symposium, "Atopic Dermatitis and Alopecia Areata: Comparison and Contrast”, held during the 2019 Annual American Academy of Dermatology meeting in Washington, DC to explore the similarities and differences between these two common but complex skin diseases and the implications from bench to bedside.
Presented at the joint International Eczema Council and National Alopecia Areata Foundation Symposium, "Atopic Dermatitis and Alopecia Areata: Comparison and Contrast”, held during the 2019 Annual American Academy of Dermatology meeting in Washington, DC to explore the similarities and differences between these two common but complex skin diseases and the implications from bench to bedside.
Presented at the joint International Eczema Council and National Alopecia Areata Foundation Symposium, "Atopic Dermatitis and Alopecia Areata: Comparison and Contrast”, held during the 2019 Annual American Academy of Dermatology meeting in Washington, DC to explore the similarities and differences between these two common but complex skin diseases and the implications from bench to bedside.
Presented at the joint International Eczema Council and National Alopecia Areata Foundation Symposium, "Atopic Dermatitis and Alopecia Areata: Comparison and Contrast”, held during the 2019 Annual American Academy of Dermatology meeting in Washington, DC to explore the similarities and differences between these two common but complex skin diseases and the implications from bench to bedside.
Presented at the joint International Eczema Council and National Alopecia Areata Foundation Symposium, "Atopic Dermatitis and Alopecia Areata: Comparison and Contrast”, held during the 2019 Annual American Academy of Dermatology meeting in Washington, DC to explore the similarities and differences between these two common but complex skin diseases and the implications from bench to bedside.
Discussion of the immune privilege collapse model of alopecia areata pathogenesis, available evidence to support this hypothetical scenario, and promising avenues for future investigation.
The FDA plans to prioritize improvements in the quality of demographic subgroup data collection, reporting and analysis, encourages greater participation of diverse patients, and supports the transparency of subgroup data. To this end, ways to recruit, engage, educate, and study those of diverse backgrounds to alopecia areata trials will be discussed.
Measuring willingness to pay in patients with alopecia areata to gauge their willingness to pay out of pocket for a cure or control of their condition.
While genome-wide association studies of common genetic variants in alopecia areata have highlighted etiological contributions from specific immune cells and pathways, exome studies of rare variants in patients and family members are implicating components of the hair follicle extracellular matrix, suggesting a crucial point of communication between the hair follicle and the immune system.
Novel induction of alopecia areata in C3H/HeJ mice shows a potential role of previously unrecognized endogenous SSEA-positive myeloid cells in driving inflammatory cascade and hair loss mechanisms.
Through in-depth interviews of key informant groups, Lilly developed a five-grade investigator global assessment (IGA) scale to measure clinically meaningful treatment response to alopecia areata treatment for patients with ≥ 50% scalp hair loss. Patient input was essential to the development of this content valid measure.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
2. Precision Medicine
“And that’s the promise of precision medicine -- delivering the right
treatments, at the right time, every time to the right person.”
- President Barack Obama, January 30, 2015
Precise definitions of disease
improve patient outcomes and decrease healthcare costs.
How do we define disease mechanisms?
3. NIH Roadmap for Precision Medicine
Adapted from Francis Collins, ASHG, 2015
Large cohorts of engaged patients
Genomic data
informs on
biology
mHealth data
informs on
environment &
behavior
EHR data
informs on
natural history and
clinical trajectories
New therapeutic interventions and companion diagnostics
Large cohorts of engaged patientsLarge cohorts of engaged patients
4. Precise definitions of disease
improve patient outcomes and decrease healthcare costs.
Precision Medicine
“And that’s the promise of precision medicine -- delivering the right
treatments, at the right time, every time to the right person.”
- President Barack Obama, January 30, 2015
Precise definitions of disease
identify patient subtypes and mechanistic links among diseases.
5. Disease subtypes and mechanistic links
disease subtypes
mechanistic link
Precisely defined disease mechanisms
are at the crux of precision medicine.
alopecia areata rheumatoid arthritis
JAK-STAT
signaling
HF
vulnerability
Costimulator
y
pathway
clinical implications
6. Disease subtypes and mechanistic links
Framework for Disease Comorbidities in Precision Medicine
Increased risk
for
Diagnosis B
A cohort of comorbid patients will be enriched for the shared disease mechanism.
Population risk
for
Diagnosis B
How do we identify comorbidities?
7. Epidemiological Studies of Comorbidities
Rzhetsky et al., 2007
Eaton et al., 2007
1. Ask the patient (lack power)
2. Look in medical records (confounding)
Type 1 diabetes
Rheumatoid arthritis
Psoriasis
Systemic lupus erythromytosis
Multiple sclerosis
Goiter (hypothyroidism)
Myositis
Type 1 diabetes
Rheumatoid arthritis
Psoriasis
Vitiligo
Thyrotoxicosis/thyroiditis
Systemic lupus erythromytosis
Inflammatory bowel disease
8. ICD co-occurrence
autoimmune rheumatoid arthritis
multiple sclerosis
systemic lupus
erythematosus
type 1 diabetes
psoriasis
inflammatory hypersensitivity angiitis
allergic rhinitis
goiter
infection susceptibility Hepatitis C
meningococcus
streptococcus
tuberculosis
virus
CNS viral disease
helicobacter pilori
mumps
Hepatitis B
pertussis
neoplasm benign neoplasms
carcinoma in situ
neurofibromatosis
metabolic
disorders of lipid
metabolism
type 2 diabetes
cholelithiasis
AA metabolism (aromatic)
neuropsychiatric depression
migraine
epilepsy
bipolar
attention deficit
EHR studies of ICD co-occurrences at CUMC
Rhetsky et al, PNAS, 2007
9. GWAS
Biological Validation with PheWAS
PheWAS (requires a cohort with genetic data linked to EHR)
Leverage Public Databases linking EHR to Genome Data
Outcome
• Groups are defined by disease status (case or control)
Exposure
• Obtain genotypes
Statistical
test
• Test for allele frequency differences between disease groups
• Identify Risk alleles
Outcome
• Groups are defined by allele status at risk SNPs (risk or protective allele)
Exposure
• Obtain all phenotypes in EHR
Statistical
test
• Test for ICD frequency differences between allele groups
• Identify comorbid condition with a biological basis
15. Dermatological Diagnoses at Columbia University
Data on 22,291 patients
17,575 only a single diagnosis
Alopecia,
unspecified AA
benign
neoplasm keratosis acne
Other
disorders of
skin and
subcutaneous
tissue
Alopecia, unspecified 2369 1701 136 227 124 331 71
AA 752 136 503 53 29 104 16
benign neoplasm 7871 227 53 4838 1172 1816 263
keratosis 5787 124 29 1172 3668 1133 57
acne 9424 331 104 1816 1133 6139 445
Other disorders of skin and subcutaneous tissue 1412 71 16 263 57 445 726
Lipid Panel Patient Counts Cholesterol Total HDL Cholesterol LDL Cholesterol Triglyceride
AA 275 187.28 56.16 108.65 116.82
acne 5864 176.55 53.03 100.25 118.64
Benign neoplasm of skin 1318 185.28 54.48 106.12 124.48
keratosis 7844 171.86 52.90 94.06 127.74
Other disorders of skin and subcutaneous tissue 1049 186.45 52.54 107.64 129.73
Unspecified alopecia 1704 183.75 54.94 105.00 120.09
Grand Total 178.10 53.49 100.28 123.88
Preliminary Results
EHR data of Human Alopecia Areata Patients
16. Alopecia areata may include disease manifestations in cells
and tissues other than hair follicle and immune system.
Disease mechanisms may contribute to dysregulation in lipid
metabolism.
Biological basis to psychosocial conditions frequently reported
by patients
Wrap up
Conclusions
Future directions
NAAF funded study of comorbidities in National Alopecia
Areata Registry. Updated the questionaire to validate
existing data.
Characterize the distribution of risk alleles for possibly
comorbid conditions in the GWAS cohort.
Leverage EHR cohorts linked to genetic data to further
pursue investigation of biological validation
17. Rheumatology
Joan Bathon
Gastroenerology
Ben Lebohwl
Govind Bhagat
Ali Jabbari
Jane Cerise
Annemieke de Jong
Zhengpeng Dai
Stephanie Erjavec
Alexa Abdelaziz
Claire Higgins
Muhammad Wajid
Sivan Harel
Yutaka Shimomura
Tarek Yamany
Esther Drill
Mazen Kurban
Hynumi Kim
Katie Fantauzzo
Courtney Luke
Rita Cabral
Gina DeStefano
Ming Zhang
Hazi Lam
Department of Dermatology
Angela M. Christiano
Julian MacKay-Wiggan
Neuropsychiatric Epidemiology
Ruth Ottman
Sharon S. Schwartz
Biomedical Informatics
Chunhua Weng
George Hripcsak
Neurology
Claire S. Riley
Cardiology
Alan Tall